# INDGN (INDGN) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/indgn

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹600.1
- Change: +1.41%
- As of: 2026-09-18
- 1D return: +1.41%
- 5D return: +3.94%
- 1M return: +5.89%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, the stock is trading at ₹600.1, showing a mixed technical picture across different timeframes. Daily and weekly indicators suggest a bullish trend, with the price trading above key moving averages (EMA 20, EMA 50, SMA 20, SMA 50, SMA 200, and Supertrend on daily; EMA 20, EMA 50, SMA 20, SMA 50, and Supertrend on weekly). This is supported by positive slopes in short-term moving averages on the daily chart. However, the monthly timeframe presents a conflicting signal, with the price below the monthly Supertrend and a bearish Supertrend direction, despite the price being above the monthly EMA 20 and SMA 20. Recent market activity shows 4 positive attention events in the last 30 days with zero downside events.

On the weekly chart, an "Outside Bar" pattern is active. The stock is positioned near the upper end of its recent trading range, with the price at 74% of the 20-period range and 92% of the 252-period range. The nearest support is identified at ₹587.01, approximately 2.18% below the current price, followed by ₹584.92. Resistance is observed at ₹601.03, just 0.16% above the current price, with further levels at ₹610.32 and ₹617.42.

Volatility is a consideration, with an annualized volatility of 33% and an Average True Range (ATR) of 2.87%. The current drawdown is -11%, with a maximum drawdown of -37% observed historically. The stock experienced a high-participation, no-clear-direction anomaly on the weekly timeframe on September 4, 2026, with a volume ratio of 3.9 and a Z-score of 3.03.

- Daily and weekly timeframes show bullish price action above key moving averages, while the monthly timeframe indicates a bearish Supertrend.
- Nearest support levels are ₹587.01 and ₹584.92.
- Nearest resistance levels are ₹601.03 and ₹610.32.
- Active patterns include a weekly "Outside Bar" and a monthly "Inside Bar" as of September 18, 2026.
- Watch for a sustained break above ₹601.03 resistance or a move below ₹587.01 support for potential trend confirmation.

- Inside Bar
- Outside Bar
- Morning Star
- Hammer
- Bearish Engulfing Reversal

### News Context

Indegene Limited has disclosed details regarding a class-action lawsuit settlement concerning its U.S. subsidiary, Indegene, Inc. The U.S. District Court for the District of New Jersey preliminarily approved a settlement on August 27, 2026, related to alleged unsolicited fax communications under the Telephone Consumer Protection Act. The settlement framework proposes a maximum fund of approximately USD 4.72 million, with individual claims capped at USD 250. The actual financial impact is contingent on the number of valid claims submitted by the December 9, 2026 deadline, with a final court approval hearing scheduled for January 12, 2027. Separately, the company has scheduled an investor meeting for September 11, 2026, in Bangalore, to provide business updates to Premji Invest.

Technically, as of September 18, 2026, the stock's daily trend indicators suggest a bullish outlook, with the closing price of ₹600.1 above its 20-day and 50-day Exponential Moving Averages (EMAs). The weekly trend also indicates a bullish Supertrend, though the monthly trend shows a bearish Supertrend. The stock has shown positive returns over various periods, including a 6-month return of 33% and a Year-to-Date (YTD) return of 15%.

- On August 27, 2026, the U.S. District Court for the District of New Jersey preliminarily approved a class-action settlement for Indegene, Inc., with a maximum fund of approximately USD 4.72 million related to alleged Telephone Consumer Protection Act violations.
- The settlement's final approval hearing is scheduled for January 12, 2027, and the financial impact depends on claims submitted by December 9, 2026.
- Indegene Limited held an investor meeting on September 11, 2026, with Premji Invest to provide business updates.
- As of September 18, 2026, the stock's daily and weekly technical trends are indicated as bullish, while the monthly trend is bearish.
- The company's stock has achieved a 33% return over the last six months and a 15% return year-to-date.

- INDEGENE LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Indegene Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Indegene Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company |SUBJECT: Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
- INDEGENE LIMITED has informed the Exchange about Pendency of any litigation(s) or dispute(s)-(Sub-para 8-Para B) |SUBJECT: Pendency of any litigation(s) or dispute(s)-(Sub-para 8-Para B)
- Indegene Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company |SUBJECT: Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

### What Changed

As of September 18, 2026, Indegene (INDGN) on the NSE has seen a slight increase in its stock price. The previous closing price on the observation date was ₹591.75, and the current price is ₹600.1. There have been no new filings or news reported for the company in the recent period. The company's profile and exchange listing remain unchanged.

- On September 18, 2026, Indegene's stock price was ₹600.1.
- The previous closing price on the observation date was ₹591.75.
- No new filings or news have been reported for Indegene.
- Indegene is listed on the NSE.

### Official Filings

Indegene Limited has disclosed developments concerning a class-action lawsuit and upcoming investor interactions. On August 27, 2026, the U.S. District Court for the District of New Jersey preliminarily approved a settlement framework for a class-action lawsuit against its wholly-owned subsidiary, Indegene, Inc. This lawsuit pertains to alleged violations of the Telephone Consumer Protection Act concerning unsolicited fax communications. The settlement establishes a maximum fund of approximately USD 4.72 million, with individual claims capped at USD 250. Importantly, the settlement operates on a claims-made and reversionary basis, meaning actual payments are contingent on the number of valid claims submitted by the December 9, 2026 deadline, and any unclaimed amounts revert to the defendants. No payments have been made to date, and the final financial impact remains uncertain pending the claims process and final court approval, scheduled for January 12, 2027. Separately, the company has been actively engaging with institutional investors and analysts. Recent disclosures indicate meetings held or scheduled in August and September 2026 with various investment firms, including Premji Invest, MFS International Singapore, ASK Investment Managers, Mirae Mutual Fund, Goldman Sachs Asset Management, and Seven Canyon Advisors, focused on providing business updates.

- On August 27, 2026, a U.S. court preliminarily approved a class-action settlement framework for Indegene, Inc. concerning alleged Telephone Consumer Protection Act violations.
- The settlement has a maximum fund of approximately USD 4.72 million, with payments of USD 250 per eligible claim, subject to a claims-made and reversionary structure.
- The deadline for claims, exclusions, and objections is December 9, 2026, with a final court approval hearing scheduled for January 12, 2027.
- Indegene Limited held and scheduled multiple meetings with institutional investors and analysts throughout August and September 2026.
- Ms. Jill Mary De Simone became a Non-Executive Independent Director effective August 13, 2026.

- INDEGENE LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Indegene Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Indegene Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company |SUBJECT: Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
- INDEGENE LIMITED has informed the Exchange about Pendency of any litigation(s) or dispute(s)-(Sub-para 8-Para B) |SUBJECT: Pendency of any litigation(s) or dispute(s)-(Sub-para 8-Para B)
- Indegene Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company |SUBJECT: Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
- INDEGENE LIMITED has informed the Exchange about Pendency of any litigation(s) or dispute(s)-(Sub-para 8-Para B) |SUBJECT: Pendency of any litigation(s) or dispute(s)-(Sub-para 8-Para B)
- Indegene Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- INDEGENE LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- INDEGENE LIMITED has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA

### Fundamentals

Indegene's recent operating performance shows a sequential increase in revenue from operations, rising from ₹942.10 crore in Q3 FY2025-26 to ₹1,063.10 crore in Q1 FY2026-27. Profit Before Exceptional Items and Tax also followed this upward trend, increasing from ₹134.70 crore in Q3 FY2025-26 to ₹152.70 crore in Q1 FY2026-27. However, Profit Before Tax experienced a dip in Q4 FY2025-26 to ₹105.10 crore from ₹134.70 crore in the preceding quarter, before recovering to ₹152.70 crore in Q1 FY2026-27. This fluctuation in Profit Before Tax, while Profit Before Exceptional Items and Tax remained more stable, suggests that exceptional items or specific non-operational factors may have influenced the reported pre-tax profit in Q4 FY2025-26. Other expenses saw a general increase over the periods, from ₹214.60 crore in Q3 FY2025-26 to ₹229.80 crore in Q1 FY2026-27. Finance costs remained relatively low, fluctuating between ₹4.60 crore and ₹7.20 crore. The company's 'Other Unallocable Expenditure Net Off Un Allocable Income' showed variability, decreasing significantly to ₹20.70 crore in Q1 FY2026-27 from ₹59.90 crore in Q4 FY2025-26.

Key monitoring areas include the trend in 'Other Unallocable Expenditure Net Off Un Allocable Income' and the factors contributing to the fluctuation in Profit Before Tax in Q4 FY2025-26, to understand the consistency of operating profitability.

- Revenue from operations increased sequentially from ₹942.10 crore in Q3 FY2025-26 to ₹1,063.10 crore in Q1 FY2026-27.
- Profit Before Exceptional Items and Tax rose from ₹134.70 crore in Q3 FY2025-26 to ₹152.70 crore in Q1 FY2026-27.
- Profit Before Tax dipped to ₹105.10 crore in Q4 FY2025-26 before recovering to ₹152.70 crore in Q1 FY2026-27.
- Other expenses increased from ₹214.60 crore in Q3 FY2025-26 to ₹229.80 crore in Q1 FY2026-27.
- Other Unallocable Expenditure Net Off Un Allocable Income decreased to ₹20.70 crore in Q1 FY2026-27 from ₹59.90 crore in Q4 FY2025-26.

### Bull Case

Indegene's technical indicators show a constructive setup across multiple timeframes as of September 18, 2026. The daily trend is bullish, supported by a closing price of ₹600.1, which is above its 20-day Exponential Moving Average (EMA) of ₹581.48 and its 50-day Simple Moving Average (SMA) of ₹553.1. The upward slope in these moving averages further reinforces the positive short-term momentum. On a weekly basis, the trend is also bullish, with the closing price exceeding both the 20-day EMA (₹543.48) and the 50-day SMA (₹515.05). The Supertrend indicator is also signaling bullish conditions on the daily and weekly charts, suggesting sustained upward movement. While the monthly trend shows a bearish Supertrend, the daily and weekly indicators point towards current strength.

- On the daily chart, the closing price of ₹600.1 is above the 20-day EMA (₹581.48) and 50-day SMA (₹553.1), with positive slopes indicating upward momentum.
- The Supertrend indicator is bullish on both daily and weekly timeframes as of September 18, 2026.
- Weekly trend analysis shows the closing price of ₹600.1 is above the 20-day EMA (₹543.48) and 50-day SMA (₹515.05).
- The stock has shown positive returns over several periods, including a 3-month return of 16% and a 6-month return of 33%.

### Bear Case

The company's monthly trend indicators suggest potential headwinds, with the Average Directional Index (ADX) at 48.33 indicating strong trending conditions, while the plus Directional Indicator (DI) at 15.6 is below the minus DI at 18.03. The Supertrend indicator is showing a bearish signal at ₹661.9. Additionally, the stock is trading below its monthly Supertrend level. The current drawdown stands at -11%, with a maximum drawdown of -37% observed historically. The annualized volatility is 33%.

- Monthly trend analysis shows a bearish Supertrend signal at ₹661.9.
- The plus DI (15.6) is below the minus DI (18.03) on the monthly chart.
- The stock is currently experiencing a drawdown of -11%, with a historical maximum drawdown of -37%.
- Annualized volatility is recorded at 33%.

### FAQs

**What is the status of the class-action lawsuit settlement involving Indegene's subsidiary?**

On August 27, 2026, the U.S. District Court for the District of New Jersey preliminarily approved a class-action settlement concerning alleged unsolicited fax communications. The settlement involves Indegene's wholly-owned subsidiary, Indegene, Inc. A maximum fund of approximately USD 4.72 million has been established, with potential payments of USD 250 per eligible claim. The actual financial impact depends on the number of valid claims submitted by the December 9, 2026 deadline. A final court approval hearing is scheduled for January 12, 2027. No payments have been made as of August 31, 2026.

**What recent investor engagement has Indegene undertaken?**

Indegene Limited has scheduled meetings with institutional investors. On September 11, 2026, a one-to-one meeting was planned with Premji Invest in Bangalore to provide business updates. The company also has other scheduled analyst or institutional investor meetings and conference calls.

**How has Indegene's stock performed recently, and what are the key technical indicators?**

As of September 18, 2026, Indegene's stock closed at ₹600.1. The stock has shown positive returns over various periods, including a 6-month return of 33% and a Year-to-Date (YTD) return of 15%. Technically, the daily trend shows a bullish Supertrend indicator at ₹554.6, with the closing price above both the 20-day and 50-day Exponential Moving Averages (EMAs). However, the monthly trend indicates a bearish Supertrend at ₹661.9, suggesting a mixed technical picture across different timeframes.

- INDEGENE LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Indegene Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Indegene Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company |SUBJECT: Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
- INDEGENE LIMITED has informed the Exchange about Pendency of any litigation(s) or dispute(s)-(Sub-para 8-Para B) |SUBJECT: Pendency of any litigation(s) or dispute(s)-(Sub-para 8-Para B)
- Indegene Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company |SUBJECT: Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
## Technical analytics

- As of: 2026-09-18
- Daily trend: Strong Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹584.92
- Risk regime: Price Risk Currently Contained

### Support levels
- 587.0093536376953
- 552.7828369140625
- 536.9397705078125

### Resistance levels
- 617.425
- 636.2249999999999
- 681.7

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +1.41% |
| return_10 | -0.01% |
| return_1m | +5.71% |
| return_1y | +2.41% |
| return_20 | +5.89% |
| return_3m | +15.72% |
| return_5 | +3.94% |
| return_6m | +32.53% |
| return_since_start | -1.10% |
| return_ytd | +15.39% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -37.14% |
| annualized_volatility | +33.00% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue Jumps Nearly 40%, but Profit Stagnates as Costs Surge

Indegene Limited reported a 39.7% rise in revenue for the quarter ended 30 June 2026 compared with the same period last year. However, profit before tax was nearly unchanged, as sharp increases in other expenses, finance costs, and unallocable expenditure absorbed the revenue gains. Sequentially, profit rebounded from the previous quarter, helped by the absence of a one-time exceptional charge and lower unallocable costs.

## Revenue Growth

Revenue from operations reached ₹1,063.10 crore in the quarter. This was 5.95% higher than the previous quarter (₹1,003.40 crore) and 39.73% higher than the year-ago quarter (₹760.80 crore). The sequential growth rate was similar to the 6.5% pace recorded in the preceding quarter.

## Profitability

Profit before tax (PBT) was ₹152.70 crore. This represents a 45.3% increase from the previous quarter’s ₹105.10 crore, but only a 0.4% rise from ₹152.10 crore in the same quarter last year.

The large sequential improvement partly reflects the absence of an exceptional item that weighed on the prior quarter. In Q4 of the previous fiscal year, an exceptional charge of ₹20.30 crore reduced reported PBT to ₹105.10 crore. Excluding that charge, underlying PBT in the prior quarter was ₹125.40 crore. On that underlying basis, PBT still grew 21.8% sequentially, outpacing the 5.95% revenue growth.

Year-over-year, however, PBT was virtually flat despite the ₹302.30 crore increase in revenue.

## Cost Pressures

The year-over-year profit stagnation coincided with significant increases in several expense lines.

- Other expenses rose 85.3% to ₹229.80 crore, from ₹124.00 crore a year earlier.
- Finance costs increased 73.0% to ₹6.40 crore, from ₹3.70 crore.
- Other unallocable expenditure (net of unallocable income) climbed to ₹20.70 crore, up from ₹6.70 crore, a 209.0% jump.

Together, these three items increased by ₹122.50 crore, absorbing a large portion of the ₹302.30 crore revenue gain. Employee benefit expense, the largest cost component, was ₹659.10 crore, representing 62.0% of revenue. The combination of these cost movements left pre-tax profit nearly unchanged from the prior year.

## Tax and Comprehensive Income

Tax expense for the quarter was ₹36.50 crore, resulting in an effective tax rate of 23.9% on the ₹152.70 crore pre-tax profit. This compares with a tax expense of ₹35.70 crore in the year-ago quarter.

Net profit was ₹116.20 crore, up 45.8% from the previous quarter (₹79.70 crore) but down 0.2% from ₹116.40 crore a year earlier.

Comprehensive income was ₹128.00 crore, a 5.0% decline from the previous quarter’s ₹134.70 crore. The drop occurred despite higher net profit, as other comprehensive income fell sharply to ₹11.80 crore from ₹55.00 crore in the prior quarter.

## Key Takeaway

Revenue grew nearly 40% year-over-year, but profit before tax was essentially flat as other expenses, finance costs, and unallocable expenditure surged. Sequentially, profit recovered strongly, aided by the absence of the prior quarter’s exceptional charge and a reduction in unallocable costs. The year-over-year profit stagnation highlights a quarter in which cost increases outpaced revenue growth.

### Ratios

## Official filings

- 2026-09-08 — Generic Announcement: Indegene Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21426_WebXMLFile_20260908_120531636.xml)
- 2026-09-08 — Generic Announcement: Indegene Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/INDEGENE_08092026120354_tofileinvestormeet_08092026.pdf)
- 2026-08-31 — Litigation Disclosure: Indegene Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/INDEGENE_31082026180841_31082026_Litigationsedisclosuresd.pdf)
- 2026-08-31 — Litigation Disclosure: Indegene Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_PARA_B_21426_WebXMLFile_20260831_181132029.xml)
- 2026-08-19 — Litigation Disclosure: Indegene Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/INDEGENE_19082026120331_tofilelitigationSEDisclosure.pdf)
- 2026-08-19 — Litigation Disclosure: Indegene Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_PARA_B_21426_WebXMLFile_20260819_121452761.xml)
- 2026-08-19 — Litigation Disclosure: Indegene Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_PARA_B_21426_WebXMLFile_20260819_121452761.xml)
- 2026-08-19 — Generic Announcement: Indegene Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/INDEGENE_19082026154846_tolfileInvestormeet19082026.pdf)
- 2026-08-19 — Generic Announcement: Indegene Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21426_WebXMLFile_20260819_155034934.xml)
- 2026-08-17 — Generic Announcement: Indegene Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_21426_WebXMLFile_20260817_122249108.xml)
- 2026-08-17 — Generic Announcement: Indegene Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/INDEGENE_17082026121650_tofilechangeindirector.pdf)
- 2026-08-17 — Generic Announcement: Indegene Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/INDEGENE_17082026121035_tofilescrutinizerreport.pdf)
- 2026-08-17 — Generic Announcement: Indegene Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/INDEGENE_17082026123423_tofiletranscriptofAGM.pdf)
- 2026-08-14 — Generic Announcement: Indegene Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/INDEGENE_14082026170852_14082026Investormeettofile.pdf)
- 2026-08-14 — Generic Announcement: Indegene Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21426_WebXMLFile_20260814_171445705.xml)
- 2026-08-13 — Generic Announcement: Indegene Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/INDEGENE_13082026185733_tofileAGMProceedings.pdf)
- 2026-08-12 — Generic Announcement: Indegene Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21426_WebXMLFile_20260812_163413899.xml)
- 2026-08-12 — Generic Announcement: Indegene Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/INDEGENE_12082026165330_tofileinvestormeet_signed.pdf)
- 2026-08-12 — Generic Announcement: Indegene Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/INDEGENE_12082026163227_tofileinvestormeet.pdf)
- 2026-08-07 — Generic Announcement: Indegene Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21426_WebXMLFile_20260807_114822319.xml)
- 2026-08-06 — Generic Announcement: Indegene Limited reported Q1 FY27 revenues of INR 10,631 million, a 39.7% year-on-year increase, with active clients reaching 105. The company expects EBITDA margins to recover to 19%-20% by Q4 FY27, driven by revenue ramp-up from new deals and productivity gains from AI initiatives. Indegene is focusing on deepening client relationships and converting its pipeline, particularly with its largest clients, while also managing margin recovery. — [Official attachment](https://nsearchives.nseindia.com/corporate/INDEGENE_06082026114946_tofileearningcalltranscript.pdf)
- 2026-08-01 — Generic Announcement: Indegene Limited published newspaper advertisements on August 1, 2026, detailing its financial results for the quarter ended June 30, 2026. The company also made this information available on its website. The filing references SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/INDEGENE_01082026123657_tofilenewspaperpublication.pdf)
- 2026-07-31 — Official Filing: Indegene Limited has disclosed an audio recording of its Q1 FY27 earnings conference call held on July 31, 2026. The call concluded at 10:05:00 AM, and the recording was uploaded to the company's website on July 31, 2026, at 10:30:00 AM. Prior intimation of the earnings call was provided to the exchange on July 10, 2026.
- 2026-07-31 — Generic Announcement: Indegene Limited has made available an audio recording of its earnings call for the quarter ended June 30, 2026, held on July 31, 2026. The recording can be accessed via a provided link and will be posted on the company's website. — [Official attachment](https://nsearchives.nseindia.com/corporate/INDEGENE_31072026123046_tfileoutcomeofearningcall.pdf)
- 2026-07-30 — Generic Announcement: Indegene Limited's Board of Directors approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, on July 30, 2026. The board also approved an allotment under the ESOP Scheme 2020. The trading window for designated persons will reopen on August 3, 2026. The auditors provided an unmodified opinion on the financial results. — [Official attachment](https://nsearchives.nseindia.com/corporate/INDEGENE_30072026190339_tofileoutcomebm30072026.pdf)

## News and market events

- 2026-08-25 — MONEYCONTROL: **Kotak downgrades Infosys, TCS to 'Add'; prefers TechM, Coforge, Hexaware, Indegene** — Kotak, Infosys, TCS, TechM, Coforge, Hexaware, Indegene — [Source](https://www.moneycontrol.com/news/business/stocks/kotak-downgrades-infosys-tcs-to-add-prefers-techm-coforge-hexaware-indegene-14015020.html)
- 2026-08-19 — Mint: **Raja Venkatraman recommends three stocks for 19 August** — Market expert Raja Venkatraman shares his top stock picks for 19 August. Here’s his technical outlook and trade strategy. — [Source](https://www.livemint.com/market/stock-market-news/raja-venkatraman-three-stocks-19-august-welspun-living-indegene-lenskart-solutions-sensex-nifty-11787071727213.html)
- 2026-08-06 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Indegene shares worth ₹1,105 crore change hands in large trade** — Sensex Today | Stock Market LIVE Updates: Sensex contracts face weekly expiry, testing the CAS system. Nifty defended 24,500, Nifty Bank defended 57,500. Over 50 major results are due today. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-hdfc-bank-aurobindo-cummins-biocon-pb-fintech-lic-trent-share-price-liveblog-19962846.htm)
- 2026-08-03 — MONEYCONTROL: **Neutral Indegene; target of Rs 570: Motilal Oswal** — Indegene, Motilal Oswal, Recommendations, Neutral — [Source](https://www.moneycontrol.com/news/business/neutral-indegene-target-of-rs-570-motilal-oswal-13992762.html)
- 2026-08-03 — MONEYCONTROL: **Indegene retains 'Neutral'; Nomura sees margin recovery from 2HFY27F, maintains Rs 500 target price** — Indegene, Indegene stocks, Indegene shares, Nomura, Indegene Q1 results — [Source](https://www.moneycontrol.com/news/business/stocks/indegene-retains-neutral-nomura-sees-margin-recovery-from-2hfy27f-maintains-rs-500-target-price-13991934.html)
- 2026-07-31 — CNBC-TV18: **Q1 Results LIVE Updates: Taj GVK revenue up 55%; ESAF SFB shares rise 7%** — Q1 Results LIVE Updates: Four Nifty companies, ITC, Maruti Suzuki, Sun Pharma and Bajaj Finserv report results today to round off this week dominated by earnings. Broader market names like Dixon Tech, Indian Oil, Glenmark Pharma, GMDC, ABB India, SJVN, GAIL and NALCO among many others will also be reporting their results. The big result reactions of the day include the likes of Swiggy, Mazagon Dock, Thermax, Bajaj Finance's earnings call and upgrades among others. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-sun-pharma-itc-maruti-suzuki-bajaj-finserv-tata-steel-swiggy-share-price-liveblog-19958383.htm)
- 2026-07-31 — CNBC-TV18: **Sensex Today | Stock Market Live Updates: Nifty extends gains to 100 pts; PSU banks off lows** — Sensex Today | Stock Market Live Updates: We are the last half the week's trade, and the Indian markets are trading on a cautious note. The Nifty is looking to close the week in green, and is trading around 24,300. The Nifty Bank is trying to hold it together, now up around 100 points, moving around 57,250. TCS, Infosys and Wipro are the top laggards. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-it-infosys-banks-tata-steel-swiggy-sun-pharma-mdl-bajaj-fin-share-price-liveblog-19958369.htm)
- 2026-07-31 — BUSINESSTODAY: **Top stocks in news: Tata Steel, Bajaj Finance, Swiggy, Mazagon, RailTel, LIC Housing, Medanta** — Stocks in news, Stocks in buzz, Stocks to buy, Stocks to watch, Bajaj Finance, Swiggy, Tata Steel, Mazagon Dock Shipbuilders, Torrent Pharmaceuticals, LIC Housing Finance, AWL Agri Business, RailTel Corporation of India, Aarti Industries, Indegene, Global Health, Chambal Fertilisers & Chemicals, Thermax, Data Patterns (India), Rainbow Children's Medicare, Satin Creditcare Network, GNG Electronics, MOIL, Nucleus Software Exports — [Source](https://www.businesstoday.in/markets/stocks/story/top-stocks-in-news-tata-steel-bajaj-finance-swiggy-mazagon-railtel-lic-housing-medanta-546413-2026-07-31)

## Business profile

**Strategic vision:** Digital commercialization services for life sciences industry.

### Business segments
- **Enterprise Commercial Solutions:** Assists life sciences companies in designing and executing omni-channel marketing campaigns, content management, and digital customer interactions.
- **Medical & Regulatory Solutions:** Supports medical writing, regulatory submissions, safety monitoring, and scientific communications.
- **Clinical & Data Solutions:** Provides clinical data management, trial operations assistance, and analytics frameworks to optimize drug development lifecycles.

### Competitive strengths
- Proprietary digital platforms
- Machine learning tools
- Automated content generation systems

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.25%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.78%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.80%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +2.21%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — +0.12%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/indgn
Markdown representation: https://faxioms.com/stocks/indgn?render=md